750 articles
AstraZeneca's baxdrostat wins FDA approval for hypertension, offering a novel mechanism for patients uncontrolled on existing therapies.
The FDA is seeking public input on repurposing approved drugs for new uses, targeting metabolic, neurodegenerative, and rare diseases.
Trastuzumab deruxtecan wins two new FDA approvals for early HER2+ breast cancer, showing dramatic survival gains over standard therapy.
A US phase II trial confirms darolutamide combined with ADT dramatically improves survival in metastatic hormone-sensitive prostate cancer.
Baxdrostat blocks aldosterone production directly, cutting systolic BP by ~15 mmHg in resistant hypertension patients who failed other drugs.
A large retrospective study finds older men with ED face 2x higher sedative abuse risk and 50%+ greater opioid and cocaine risk.
New research finds eating grapes daily for two weeks alters skin gene expression, boosting UV protection and cutting oxidative stress markers.
Repair Biotechnologies' REP-0004 uses mRNA-lipid nanoparticles to clear toxic free cholesterol from the liver, reversing plaque and liver disease.
Fractyl Health's RJVA-001 aims to trigger lasting GLP-1 production from a single dose, as oral and multi-action obesity drugs also advance rapidly.
Cambridge-backed PREMAZ measures memory precision to catch Alzheimer's warning signs far earlier than standard cognitive tests.
A targeted RNA interference therapy slashed liver fat nearly in half in 12 weeks for patients with a common genetic variant tied to fatty liver disease.
A new health tech partnership merges diabetes management with cardiovascular monitoring to tackle cardiometabolic risk before complications arise.
